Comment on

• Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5.

  Parulekar WR, Day AG, Ottaway JA, Shepherd LE, Trudeau ME, Bramwell V, Levine M, Pritchard KI; National Cancer Institute of Canada Clinical Trials Group. Parulekar WR, et al. J Clin Oncol. 2005 Sep 1;23(25):6002-8. doi: 10.1200/JCO.2005.07.096. J Clin Oncol. 2005. PMID: 16135468
• Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer.

  Walshe JM, Denduluri N, Swain SM. Walshe JM, et al. J Clin Oncol. 2006 Dec 20;24(36):5769-79. doi: 10.1200/JCO.2006.07.2793. Epub 2006 Nov 27. J Clin Oncol. 2006. PMID: 17130515 Review.
• Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.

  Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, Fischer D, Sommer HL, Conrad B, Ortmann O, Fehm T, Rezai M, Mehta K, Loibl S; German Breast Group Investigators. Gerber B, et al. J Clin Oncol. 2011 Jun 10;29(17):2334-41. doi: 10.1200/JCO.2010.32.5704. Epub 2011 May 2. J Clin Oncol. 2011. PMID: 21537042 Clinical Trial.
• Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.

  Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE. Munster PN, et al. J Clin Oncol. 2012 Feb 10;30(5):533-8. doi: 10.1200/JCO.2011.34.6890. Epub 2012 Jan 9. J Clin Oncol. 2012. PMID: 22231041 Free PMC article. Clinical Trial.